Compare Biogen Inc (BIIB) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Danaher Corporation — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Danaher Corporation trades at $207.45 (market cap $145.83B). The key difference: Danaher Corporation is far larger — about 4.8× Biogen Inc's market cap, and Danaher Corporation pays a 0.77% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | DHR | |
|---|---|---|
Market Cap | $30.13B | $145.83B |
Sector | Health | Health |
52-Week High | $216.63 | $242.05 |
52-Week Low | $132.22 | $161.91 |
Enterprise Value | $37.20B | $168.04B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Danaher (DHR) trades at $207.44, down 0.87% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company demonstrates solid fundamentals with consistent earnings beats in recent quarters and a healthy 15.95% net income margin. Recent developments include the Masimo acquisition approval and new product launches in the SCIEX division, supporting growth prospects in biotechnology and life sciences segments.
DHR presents a mixed outlook with strong analyst support (69% buy ratings) but faces valuation concerns at a P/E of 36.98. Key opportunities include biotechnology segment growth and strategic acquisitions, while risks involve elevated valuation, competitive pressures, and potential market volatility. The stock trades above the consensus price target of $202.33, suggesting limited near-term upside despite positive fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
